Oncology

Olaparib (Lynparza) is indicated to treat HER2-negative metastatic breast cancer with BRCA mutations.

Advancing biomarker research may help determine which patients with non-invasive breast cancer will develop invasive disease.

Ribavirin steady-state serum levels correspond to high rates of efficacy and low adverse effect from direct-acting antiviral drugs for difficult-to-treat hepatitis C virus.

The path to a hepatitis C vaccine is yielded by the virus’ virulent nature and its evasiveness to immune responses.

Conflicting breast cancer treatment guidelines can leave many decisions to the discretion of the provider.

Sofosbuvir/velpatasvir is the first direct acting antiviral therapy registered for use against all 6 genotypes of hepatitis C.

Cisplatin and platinum-based chemotherapies cause hearing loss in up to 80% of adults and more than 50% of children.

Despite the benefits of oral oncolytics, high out-of-pocket costs could put treatment out of reach for patients with cancer.

A small number of liquid biopsy test results from different providers matched for overlapping genetic sequences.

Providing information about breast cancer surgery via an online tool may help patients feel more informed about their treatment options.

The Centers for Medicare and Medicaid Services finalized a ruling that slashes reimbursement rates on drugs that qualify under the 340B program.

Oral regimen of ledipasvir and sofosbuvir for hepatitis C virus shows improved treatment outcomes.

GammaPod system can accurately deliver radiation therapy to breast tumors.

Cigarette smoking played a role in 19% of cancers and 29% of cancer-related deaths in 2014.

Enzymes that protect the immune system may malfunction and provoke cancer-related mutations.

Pembrolizumab plus trastuzumab may overcome drug-resistance among patients with advanced HER2+ breast cancer.

Top news of the week from Specialty Pharmacy Times.

Trastuzumab is an oncology biologic drug that is indicated for multiple types of cancer.

Officials with the FDA have approved pertuzumab (Perjeta, Roche) in combination with trastuzumab and chemotherapy as an adjuvant therapy for patients with early-stage human epidermal growth factor receptor 2 positive (HER2+) breast cancer who are at high risk of experiencing recurrence.

Pertuzumab (Perjeta) plus trastuzumab and chemotherapy improved invasive disease-free survival in patients with HER2+ breast cancer.

Bosutinib (Bosulif) was approved by the FDA to treat patients with chronic phase Philadelphia chromosome positive chronic myelogenous leukemia.

Trastuzumab (Herceptin) is indicated to treat HER2+ breast and gastric cancers.

Patients treated with chemotherapy biweekly were 17% less likely to experience breast cancer recurrence over 10 years.

The average profit from cancer drugs administered by 340B hospitals was nearly 50% in 2015.

Top news of the week from Specialty Pharmacy Times.

Centers for Medicare & Medicaid Services proposed national coverage determination of the FoundationOne CDx test.

Women with type 2 diabetes were 43% more likely to develop estrogen receptor negative breast cancer than patients without diabetes.

Screening for HBV among high-risk populations is crucial to stopping transmission of the virus.

The FDA has approved trastuzumab-dkst (Ogivri, Mylan GmbH) as a biosimilar to trastuzumab (Herceptin, Genentech), the first biosimilar for the treatment of certain breast and stomach cancers.

Rising cancer drug costs have become inreasingly worrisome for patients and health care providers. Despite the entry of competitors in the market, treatment costs continue to climb over time, according to a study recently published by the Journal of Clinical Oncology.